OraSure Technologies heads into its third-quarter report with a credibility test that has little to do with its pipeline and everything to do with its core business. Last quarter delivered the cleanest evidence yet that the company's long-advertised transition year was giving way to growth, with revenue climbing nearly 10% sequentially and gross margins expanding again. The same call also removed the most exciting near-term catalyst, the IntelliQuick molecular self-test for chlamydia and gonorrhea, from the 2026 calendar. With that product no longer coming this year, the existing business now has to carry the story on its own.
The Street is looking for revenue of about $31.1 million, up 15% from $27.1 million a year ago and a touch above the $30.6 million posted in the second quarter. That lands just above the midpoint of management's $29.5 million to $32.5 million guidance range, so analysts are not asking for heroics. Consensus calls for a loss of $0.22 per share, roughly in line with last quarter's $0.23 loss but wider than the $0.17 loss a year earlier. That combination of double-digit top-line growth and a deeper year-over-year loss tells you the company is still spending ahead of revenue, which is why the margin and cash trends matter as much as the sales figure.
The biggest question is durability. Management acknowledged that some of the second quarter's U.S. strength was tied to customers' fiscal-year purchasing cycles, and the guidance for flattish sequential revenue quietly concedes that some of that demand may have been pulled forward. A result near or above the top of the range would suggest the diagnostics surge, driven by public health demand, syphilis testing and new Sickle Scan sales, rests on firmer footing than a budget flush. A print near the low end, particularly if diagnostics slips back from $19.4 million, would revive concerns about federal public health funding pressure. On the specimen collection side, the early recovery in academic research and advanced genetic labs needs to show it was not a one-quarter blip.
The newer products should start to leave fingerprints. The ColiP DX urine collection kit, cleared in June for eight STI indications on Roche's Cobas platform, now has a full quarter of commercial availability, and any color on early adoption would help fill the hole left by IntelliQuick. The Ebola 2.0 emergency authorization and the favorable draft guidance in the U.K. for an endometriosis test built on the company's collection technology are smaller but welcome signs of breadth. Investors should also expect an update on the IntelliQuick resubmission timeline, since a vague answer would leave the 2027 growth narrative looking thin.
Margins and cash are the other half of the test. Non-GAAP gross margin has improved to 44.2% from 41.4% two quarters earlier, and management guided to similar levels this quarter, so any slippage would undercut the operating discipline story. Cash fell to $161 million from $216 million over three quarters and buybacks were throttled back, making the pace of burn central to the reaffirmed target of reaching operating cash flow breakeven entering 2027.
The market has been skeptical. Shares have fallen about 5% since the last report, trailing the S&P 500 by roughly three percentage points, and sentiment sits essentially neutral with the faintest bearish tilt. At $3.94, the stock trades comfortably above its 200-day moving average of $3.51 and in the upper half of its post-earnings range, though still well short of the $4.38 high. Ultimately, this report will determine whether the second quarter marked a genuine turn in OraSure's core franchise or a seasonal bump that left the company waiting on a delayed pipeline to rescue its growth story.